|
|
Blood, 1 December 2005, Vol. 106, No. 12, pp. 3948-3954.
Prepublished online as a Blood First Edition Paper on August 16, 2005; DOI 10.1182/blood-2005-06-2209.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
Shinya Kimura,
Haruna Naito,
Hidekazu Segawa,
Junya Kuroda,
Takeshi Yuasa,
Kiyoshi Sato,
Asumi Yokota,
Yuri Kamitsuji,
Eri Kawata,
Eishi Ashihara,
Yohei Nakaya,
Haruna Naruoka,
Tatsushi Wakayama,
Kimio Nasu,
Tetsuo Asaki,
Tomoko Niwa,
Kazuko Hirabayashi, and
Taira Maekawa
From the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan; and Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan.
Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region–Abl (Bcr-Abl)–positive leukemia, resistance is often reported in patients with advanced-stage disease. Although several Src inhibitors are more effective than imatinib and simultaneously inhibit Lyn, whose overexpression is associated with imatinib resistance, these inhibitors are less specific than imatinib. We have identified a specific dual Abl-Lyn inhibitor, NS-187 (elsewhere described as CNS-9), which is 25 to 55 times more potent than imatinib in vitro. NS-187 is also at least 10 times as effective as imatinib in suppressing the growth of Bcr-Abl–bearing tumors and markedly extends the survival of mice bearing such tumors. The inhibitory effect of NS-187 extends to 12 of 13 Bcr-Abl proteins with mutations in their kinase domain but not to T315I. NS-187 also inhibits Lyn without affecting the phosphorylation of Src, Blk, or Yes. These results suggest that NS-187 may be a potentially valuable novel agent to combat imatinib-resistant Philadelphia-positive (Ph+) leukemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Jabbour, J. E. Cortes, and H. M. Kantarjian
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Mayo Clin. Proc.,
February 1, 2009;
84(2):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Haematologica,
August 1, 2008;
93(8):
1145 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Tam, H. Kantarjian, G. Garcia-Manero, G. Borthakur, S. O'Brien, F. Ravandi, J. Shan, and J. Cortes
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Blood,
August 1, 2008;
112(3):
516 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Puttini, S. Redaelli, L. Moretti, S. Brussolo, R. H Gunby, L. Mologni, E. Marchesi, L. Cleris, A. Donella-Deana, P. Drueckes, et al.
Characterization of compound 584, an Abl kinase inhibitor with lasting effects
Haematologica,
May 1, 2008;
93(5):
653 - 661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist,
April 1, 2008;
13(4):
424 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C. E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.-B. Rios, L. Calvert, et al.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Mol. Cancer Ther.,
January 1, 2008;
7(1):
48 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Melo and C. Chuah
Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond
Hematology,
January 1, 2008;
2008(1):
427 - 435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Clin. Cancer Res.,
February 15, 2007;
13(4):
1089 - 1097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges
Hematology,
January 1, 2007;
2007(1):
435 - 443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yokota, S. Kimura, S. Masuda, E. Ashihara, J. Kuroda, K. Sato, Y. Kamitsuji, E. Kawata, Y. Deguchi, Y. Urasaki, et al.
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
Blood,
January 1, 2007;
109(1):
306 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yokota, S. Kimura, S. Masuda, E. Ashihara, Y. Urasaki, Y. Terui, M. Ruthardt, T. Ueda, K. Hatake, K.-i. Inui, et al.
Cyclosporin A, a P-gp Inhibitor, Augments the Anti-Central Nervous System Ph+ Leukemia Effects of INNO-406.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
834 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Tao, T. Sun, A. R. Craig, J. E. Cortes, O. G. Ottmann, A. Hochhaus, P. E. Reddy, H. M. Kantarjian, and R. B. Arlinghaus
The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.
Blood (ASH Annual Meeting Abstracts),
November 1, 2006;
108(11):
2179 - 2179.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
Blood,
October 1, 2006;
108(7):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama and J. E. Cortes
Chronic Myeloid Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
July 1, 2006;
81(7):
973 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
